Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
October 18 2019 - 08:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that results from the
Phase 2 MoveDMD trial and open-label extension with edasalonexent
in boys affected by Duchenne muscular dystrophy (DMD) will be
presented at the Child Neurology Society 48th Annual Meeting to be
held October 23-26 in Charlotte, North Carolina.
Richard Finkel, M.D., Chief, Division of Neurology, Department
of Pediatrics at Nemours Children’s Health System and a Principal
Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies
of edasalonexent, will give an oral presentation titled “Treatment
of Young Boys with Duchenne Muscular Dystrophy with the NF-kB
Inhibitor Edasalonexent Showed a Slowing of Disease Progression as
Assessed by MRI and Functional Measures” during Platform Session 1
on Friday, October 25th at 9:00am ET.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. Our
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being dosed in the open-label extension trial
GalaxyDMD. In our MoveDMD Phase 2 trial and open-label extension,
we observed that edasalonexent preserved muscle function and
substantially slowed disease progression compared to rates of
change in a control period, and significantly improved biomarkers
of muscle health and inflammation. The FDA has granted orphan drug,
fast track, and rare pediatric disease designations and the
European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about
future clinical trial plans including, among other things,
statements about the Company’s global Phase 3 PolarisDMD trial in
DMD to evaluate the efficacy and safety of edasalonexent for
registration purposes, including the anticipated timing for
top-line results, potential timing for the filing of an NDA, and
other statements containing the words “believes,” “anticipates,”
“plans,” “expects,” “may” and similar expressions, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
inherent in the initiation and completion of preclinical studies
and clinical trials and clinical development of the Company’s
product candidates; whether interim results from a preclinical or
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products; availability of
funding sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements; other
matters that could affect the availability or commercial potential
of the Company’s product candidates; and general economic and
market conditions and other factors discussed in the “Risk Factors”
section of the Company’s Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2019, which is on file with the
Securities and Exchange Commission, and in other filings that the
Company may make with the Securities and Exchange Commission in the
future. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191018005052/en/
Investor and Media Contact Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2023 to Mar 2024